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Abstract
When introduced in the 1950s, benzathine penicillin G (BPG) was shown to be effective in eradicating group A beta-hemolytic
streptococcus (GAS) for at least 3 weeks after administration. Several studies since the 1990s suggest that at 3–4 weeks serum
penicillin G levels are less than adequate (below MIC
90 of 0.016 mg/ml). We studied these levels for 4 weeks after the
recommended dose of BPG in military recruits, for whom it is used as prophylaxis against GAS. The 329 subjects (mean age 20
years)eachreceived1.2millionunitsBPGIMandgavesera1daypostinjectionandtwicemoreatstaggeredtimepointsover4
weeks. Serum penicillin G levels were measured by liquid chromatography/tandem mass spectometry. The half-life of serum
penicillinG was4.1days. Byday11,mean levels were,0.02 mg/ml,andbyday15,0.01 mg/ml.Levelsinmorethan50% of the
subjects were below 0.02 mg/ml on day 9, and ,.01 mg/ml on day 16. There was no demonstrable effect of subject body-
surfacearea norofthe fourdifferentlots ofBPGused. Thesedata indicatethatinhealthy young adultsserumpenicillin G levels
become less than protective ,2K weeks after injection of 1.2 million units of BPG. The findings require serious consideration
in future medical and public health recommendations for treatment and prophylaxis of GAS upper respiratory tract infections.
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Introduction
Benzathine penicillin G (BPG) has been a mainstay of treatment
and prophylaxis against group A beta-hemolytic streptococcus
(GAS) since its clinical introduction in the early 1950s [1]. Studies
by Rusoff and Stollerman [2] demonstrated that this repository
form of penicillin provided adequate serum levels for both
treatment of GAS as well as for prevention of acquisition of
group A streptococci for 3 weeks or longer following injection at
recommended BPG doses.
BPG remains an integral part of most recommendations/
guidelines for management of GAS upper respiratory tract
infections [3,4,5]. Its primary advantages include improved
compliance over oral preparations, and improved effectiveness
even when compliance has been documented [6]. It has proved
effective in both endemic and epidemic GAS disease, especially in
military populations where streptococcal infections have historically
been and remain significant medical and public health problems.
Recently, unexpectedly high streptococcal treatment failure
rates were reported when treating streptococcal pharyngitis with
BPG [6]. The duration of adequate serum penicillin levels for
GAS is dose-dependent; the larger the dose of BPG, the higher the
serum concentration for longer periods of time [7]. A BPG study
by Bass et al. [8]—the only relatively recent study (1996) in
otherwise healthy adults—reported that serum penicillin levels
were below assayable levels at less than three weeks following BPG
injection in healthy military trainees. We performed a meta-
analysis that indicates that there has been, since the studies of the
1990s, a reduction in the probability that at 3 weeks a protective
level of BPG serum will be maintained, whether expressed by
percentage of subjects above the anticipated serum penicillin levels
or by means of serum penicillin levels in study subjects (Broderick,
Faix, and Hansen, unpublished data).
Failure of microbiological treatment and faster-than-expected
clearance in light of unchanged susceptibility of GAS to penicillin
[9,10] hamper the effective use of currently available BPG. If
current formulations of BPG result in pharmacokinetic profiles
that result in lower than anticipated levels relative to the past
reports, the adverse consequences for BPG treatment and
prophylaxis would be significant [7].
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administration of 1.2 million units initially and every 3or 4 weeks,
depending on the nature of the illness and the health status of the
individual [3]. The purpose of this study was to examine the
pharmacokinetics of the currently available intramuscular BPG
preparation in the United States in a high-risk population.
Methods
Ethics statement
The study was approved by the Naval Health Research Center
institutional review board (protocol number NHRC.2007.0022).
All participants provided informed written consent.
Subjects
In January 2008, 164 newly reporting military trainees were
enrolled in the study after being briefed on study procedures and
providing written informed consent. In March 2008 an additional
165 subjects were enrolled. Each of these two cohorts was followed
for 29 days after enrollment. Enrollment was limited to male
trainees (no females train at the military training facility) who were
not allergic to penicillin and had no history of rheumatic fever or
rheumatic heart disease. None had received antibiotics recently.
Procedure
On day 0, as part of standard military medical processing for
initial entry training, subjects were administered an intramuscular
(gluteal) dose of 1.2 million units of BPG (Monarch Pharmaceu-
ticals [subsidiary of King Pharmaceuticals] L-A 2 ml Bicillin;
NDC number 60793070110; mfg. cat. no. 1138883). Doses from
four manufactured lots were equally divided among the subjects
and the lot number was recorded for each subject. No additional
BPG doses or other penicillin or penicillin related antibiotics were
administered during the study. Four percent of the subjects
received a non-penicillin-type of antibiotic some time during the
study which would not have been detected. Body-surface area was
calculated for each subject using self-reported height and weight
[11].
The protocol was identical for each cohort. Each subject gave
blood three times. The first time for all subjects was approximately
24 hours after the BPG injection. The subjects were then
randomly assigned to 1 of 10 groups of between 24–36 subjects
which were kept intact for their two subsequent blood draws. The
groups were staggered for administration of the blood draws as
shown in Table 1.
Each blood draw consisted of two 10 ml serum-separator tubes.
The blood was allowed to clot at room temperature for
20 minutes, centrifuged at 2000 rpm for 15 minutes, and serum
transferred into two 4 ml cryogenic vials labeled with the subject’s
study ID and date of collection; all samples were then stored at
270uC.
Laboratory analysis
The sera were analyzed (blinded to subject, date, and order of
collection) for penicillin G levels using liquid chromatography
mass spectroscopy (LC/MS/MS). A 1.0 mL aliquot of serum was
extracted with 4.0 mL of acetonitrile. After vortexing and
centrifugation the organic layer was transferred to a clean tube,
dried with a stream of nitrogen at 40uC, then reconstituted in
mobile phase for injection a Varian 1200L LC/MS/MS in the
ESI (electrospray ionization) mode. Separation on the high
pressure liquid chromatography was achieved using a Polaris 5 m
C18-A, 5062.0 mm column (Sigma-Aldrich, St. Louis, MO). The
mobile phase was A: 0.1% Acetic Acid and B: methanol +0.1%
acetic acid with a gradient of 10% to 50% B in 8 minutes. The
internal standard penicillin V was measured by single reaction
monitoring. Penicillin G was measured at the 335.1 (parent mass)
transition to 160.0 (fragment mass) and the internal standard at the
365.1(parent mass) transition to 160.0 (fragment mass). The limit
of quantitation of this procedure was 500 pg/ml.
Statistical analysis
Analysis of variance (ANOVA) was performed to evaluate
differences in serum levels between the two cohorts, among the
four lots of BPG, and among quartiles of body surface size, and to
examine the relationship of each of these factors with day since
injection. Mean serum penicillin G levels and proportion of
subjects above putative protection levels were calculated for each
day. Simple linear regression was used to evaluate the relationship
between body surface area and serum penicillin G concentrations
on the first day after injection. Where no difference was noted
between cohorts they were collapsed for analysis. The least-squares
method was used to fit an exponential curve to the daily
measurements and to estimate the half-life of serum penicillin G
following the injection.
We made no assumptions regarding the kinetics of serum
penicillin levels and sampled our study population throughout the
29-day period of observation. This provided a continuous profile
of serum penicillin G levels, rather than the limited time points
that have been reported in most previous studies.
Results
A total of 329 male subjects (mean age=20 years [Table 2])
were enrolled; a total of 953 blood samples (average of 2.9 samples
per subject) were collected.
There were no significant differences in serum levels between
cohorts. One subject whose serum never showed detectable
penicillin levels was removed from analysis since the study was
designed to measure changes in detectable levels. The cause for
this could not be determined. One subject had serum penicillin G
levels consistent with the other subjects at days 1 (0.073 mg/ml)
and 8 (0.003 mg/ml) but had an extremely high value for day 22
(0.1485 mg/ml vs. mean of 0.006 and range 0 to 0.026 for the rest
of the subjects). This apparent outlier was excluded from the day
22 mean penicillin G serum level calculation.
Table 1. Plan for blood draws.
Group
BPG dose
all on day 0
Draw 1
all on day 1 Draw 2 Draw 3
1 Day 3 Day 16
2 Day 4 Day 17
3 Day 6 Day 20
4 Day 7 Day 21
5 Day 0 Day 1 Day 8 Day 22
6 Day 9 Day 23
7 Day 10 Day 24
8 Day 13 Day 27
9 Day 14 Day 28
10 Day 15 Day 29
Each cohort had 10 groups, and each group had between 12 and 18 subjects.
doi:10.1371/journal.pone.0025308.t001
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enrollment cohorts or the four BPG lots (data not shown). There
was no evidence of interaction between cohort, BPG lot or body
size and day since injection. Day since injection was the only
significant contributor to serum penicillin G level.
The half-life of serum penicillin levels for the study subjects was
4.1 days in the exponential model. Table 3 and Figure 1 show the
relationship between mean daily serum penicillin G levels and
their 95% confidence intervals. The mean serum penicillin level
fell below putative protection levels at different days. From day 9
on, the mean level was less than 0.03 mg/ml; from day 11 on the
mean level was less than 0.02 mg/ml; and from day 15 on the
mean was less than 0.01 mg/ml.
Figure 2 shows that 50% of the subjects were below 0.03 mg/ml
at 6 days, below 0.02 mg/ml at 9 days, and below 0.01 mg/ml at
16 days.
Discussion
The ‘‘protective’’ penicillin G serum level reflects minimum
inhibitory concentration (MIC). Minimum levels of protection
have been proposed between 0.01 and 0.03 mg/ml (Broderick,
Faix and Hansen, unpublished data). Regardless of the minimum
protective concentration adopted (0.01, 0.02, 0.03 mg/ml), serum
penicillin G levels in this population of active individuals fall to
subprotective levels in less than 2.5 weeks from initial injection.
Given the findings of Kaplan and Johnson [12] regarding GAS
pharyngitis treatment failures in a pediatric population, and the
results of the Bass et al. study [8] showing accelerated declines in
serum levels than expected in adults, the results from the present
study have important clinical implications.
These results are consistent with those of Bass et al. [8], the only
other study on a similar healthy and active young-adult
population, and contradict previous studies on persistence of
serum penicillin. There are several possible explanations. There
could be a difference in the bioavailability of penicillin in the
currently manufactured product due to changes in the manufac-
turing process during the past 50 years. A 1992 study indicated
that the duration of adequate serum penicillin G levels varies
significantly by manufacturer [13]. To our knowledge, there are
no recent studies of the bioavailability of penicillin following
transfer of the manufacturing process that occurred in 2008. At
that time, the manufacturing process for BPG in the United States
was sold by Wyeth Laboratories to Monarch Pharmaceuticals.
Despite an intensive effort, we have been unable to find any
published detailed description to allow a comparison of the
manufactured product when the initial studies were carried out in
the early 1950s and the currently available BPG from the
successor manufacturer in the United States.
Another important consideration is the activity level of the
subjects. Bass et al. [8] reported low serum penicillin levels in
Table 2. Demographics of study subjects.
Demographics Cohort 1 mean (range) Cohort 2 mean (range) Overall mean (range)
No. of subjects n=164 n=165 n=329
Age (y) 20, 17–27 20, 18–32 20, 17–32
Height (in) 70, 63–76 69, 57–77 70, 57–77
Weight (lb) 167, 110–240 170, 115–237 169, 110–240
Body surface area groups by quartile (sq m) Quartile 1 1.52–1.81 1.53–1.82 1.52–1.81
Quartile 2 1.82–1.92 1.83–1.93 1.82–1.92
Quartile 3 1.93–2.05 1.94–2.04 1.93–2.05
Quartile 4 2.06–2.41 2.05–2.61 2.05–2.61
doi:10.1371/journal.pone.0025308.t002
Table 3. Mean serum penicillin G levels and 95% confidence







1 325 0.119 0.0000.259
2 4 0.080 0.029–0.131
3 25 0.086 0.019–0.152
4 32 0.056 0.013–0.099
5 4 0.062 0.049–0.075
6 31 0.043 0.000–0.092
7 36 0.030 0.001–0.059
8 27 0.025 0.000–0.059
9 32 0.021 0.007–0.034
10 32 0.018 0.002–0.035
12 7 0.016 0.000–0.034
13 29 0.016 0.000–0.036
14 33 0.011 0.000–0.025
15 31 0.012 0.000–0.032
16 29 0.009 0.000–0.022
17 27 0.012 0.000–0.026
19 5 0.010 0.000–0.020
20 26 0.011 0.000–0.028
21 35 0.008 0.000–0.020
22 25 0.012 0.000–0.024
23 28 0.006 0.000–0.015
24 28 0.006 0.000–0.015
26 6 0.007 0.000–0.020
27 29 0.005 0.000–0.017
28 27 0.004 0.000–0.012
29 31 0.004 0.000–0.004
doi:10.1371/journal.pone.0025308.t003
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was due to the active daily routine of these individuals. That study
was carried out using the BPG preparation when it was
manufactured by the former pharmaceutical company, but those
data are generally similar to our findings in the present study. A
review of the literature suggests that there may be a difference in
penicillin G persistence in studies on people with illness (primarily
rheumatic fever/heart disease) and studies on healthy subjects
[8,14,15,16].
The clinical implications of our findings are important for the
active young adult population, and suggest that a similar study be
conducted in children. At issue is the effectiveness of protection
given by BPG for rheumatic fever prevention in the weight group
we studied if adequate levels are present for only half the duration
currently anticipated. In order to maintain adequate levels either
the dose or the frequency of dosing should be increased, or both.
For example, in a study of patients ranging in age from 16 to 49
years, Currie et al. [7] found that increasing the dose above 1.2
million units of BPG resulted in higher serum penicillin G levels
for longer periods of time. If a pharmacokinetic profile similar to
the one we have shown in this study is found in children, then we
would have the same concerns for adequate protection and
appropriate dosing.
These findings also have important implications for the use of
BPG in the treatment of and prophylaxis for a variety of other
conditions. At the military training facility where this study was
conducted, GAS-related respiratory disease is generally well
controlled by a BPG injection every 4 weeks. In case of an
outbreak, administration of BPG every 2 weeks might be
appropriate. Frequency of dosing was increased during a 2002
outbreak of GAS pneumonia along with other interventions such
as isolation of ill trainees, cohorting incoming groups, and
providing other antibiotics for prophylaxis in penicillin-allergic
trainees, which ended the outbreak [17]. As an additional example
of the clinical implications of our study, the recommended doses
for syphilis treatment are higher than for group A streptococcus-
related illnesses (2.4 million units every 7 days). In light of our
findings current recommendations for this infection should be re-
evaluated not only in adults, but also when treating congenital
syphilis in infants.
For treatment of GAS upper respiratory tract infection in
children, recent studies have demonstrated failure to eradicate the
organism from 35 to 40% of individuals with documented positive
throat cultures [12]. Whether this is the result of suboptimal serum
penicillin levels or other possibilities such as the streptococcal
upper respiratory-tract carrier state remains unknown. Further-
more, it has been re-emphasized that since penicillin does not
penetrate well into epithelial cells, lowering the serum-epithelium
gradient could well have an adverse effect [18]. These issues are of
practical clinical and public health importance and require further
study, as well as further consideration in currently available clinical
guidelines.
In this population of young healthy adults, penicillin G serum
levels degraded more quickly than would have been expected from
review of the pharmacokinetics literature. The shorter duration of
protective serum levels has implications for the treatment and
prevention of diseases related to GAS and other indicated
pathogens.
Figure 1. Mean BPG level and 95% confidence interval versus day since injection. Each subject provided a sample 1 day after injection and
two more over the course of 28 days. The serum penicillin G half life is 4.1 days. At approximately day 11 the expected mean penicillin G serum level
is less than 0.02 mg/ml. On days 1, 2 and 3 the 95% confidence intervals extend upward beyond 0.13 and are truncated to allow more visual
resolution at the lower end of the curve. (Note: day 21 outlier removed from calculation of mean; see text.).
doi:10.1371/journal.pone.0025308.g001
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